Drug Profile
Research programme: antibacterials - Alchemia
Alternative Names: Antibacterials research programme - Alchemia; VT 16773Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Alchemia
- Class Small molecules
- Mechanism of Action Peptidoglycan glycosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Australia
- 07 May 2010 Preclinical development is ongoing in Australia
- 09 Aug 2006 Optimisation studies are ongoing